Chou, Jonathan

Remodelling the extracellular matrix in development and disease

Bonnans, C., Chou, J., & Werb, Z. (2014) · Nature Reviews Molecular Cell Biology

Protease and Inhibitor MechanismsCellular Mechanics and Interactions

Cited by 4,367

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J. J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., et al. (2018) · Cell

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 733

Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial

Aggarwal, R., Starzinski, S., de Kouchkovsky, I., Koshkin, V., Bose, R., Chou, J., Desai, A., Kwon, D., Kaushal, S., Trihy, L., et al. (2023) · The Lancet Oncology

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 104

An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer

Das, R., Sjöström, M., Shrestha, R., Yogodzinski, C., Egusa, E. A., Chesner, L. N., Chen, W. S., Chou, J., Dang, D. K., Swinderman, J. T., et al. (2021) · Nature Communications

Prostate Cancer Treatment and ResearchChromatin Remodeling and Cancer

Cited by 38

Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer

Li, H., Melnyk, J. E., Fu, B. X. H., Shrestha, R., Zhang, M., Sjöström, M., Feng, S., Anderson, J. A., Han, W., Chesner, L. N., et al. (2025) · Nature Genetics

Prostate Cancer Treatment and ResearchChromatin Remodeling and Cancer

Cited by 10

A phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant prostate cancer (mCRPC).

Shakhnazaryan, N., Curry, N., Rastogi, M., Avins, D., Pandey, S., de Kouchkovsky, I., Kwon, D., Desai, A., Fitzgerald, K. N., Bose, R., et al. (2024) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 6

Data from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin

Chu, C. E., Sjöström, M., Egusa, E. A., Gibb, E. A., Badura, M. L., Zhu, J., Koshkin, V. S., Stohr, B. A., Meng, M. V., Pruthi, R. S., et al. (2023)

Bladder and Urothelial Cancer TreatmentsUrinary Bladder and Prostate Research

Cited by 0

Data from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin

Chu, C. E., Sjöström, M., Egusa, E. A., Gibb, E. A., Badura, M. L., Zhu, J., Koshkin, V. S., Stohr, B. A., Meng, M. V., Pruthi, R. S., et al. (2023)

Bladder and Urothelial Cancer TreatmentsUrinary Bladder and Prostate Research

Cited by 0